AEGiS-15IAC: Antiretroviral resistance mutations among HIV positive pregnant women.

15th International AIDS Conference


Bangkok, Thailand - July 11-16, 2004

DonateNow
Print this article

Antiretroviral resistance mutations among HIV positive pregnant women.

Int Conf AIDS 2004 Jul 11-16; 15:(abstract no. B10049)

Edeh CN, Babaoye G
HEAL Concept, Abuja, Nigeria

BACKGROUND: AZT has been routinely offered to HIV pregnant women to prevent HIV transmission from mother to child. Multi-drug ARV regimens are increasingly used for treatment. Viral resistance and its relative role in vertical; transmission and subsequent pediatric clinical course are important to understand especially in the context of increasing drug resistance.

METHODS: Pregnant women who received AZT during pregnancy between 1999 -2001 were selected for genotyping. Data for reverse transcriptase and protease genes were generated for 168 plasma samples.

RESULTS: Mutations associated with AZT resistance were present in 17% (321 168, 22 being single mutants, 6 being dual and 4 being more than two. Six mothers had the 3TC associated mutation. Only 3 women had any Nevirapine associated mutations while there were no major mutations associated with protease inhibitor (PI) use. However, 70% had at least one minor mutation associated with PIs of questionable significance in this low PI exposure cohort. Among 34 infected infants there was no association between ARV' resistance mutations and transmission. The detection of marternal ARV resistance mutation exhibited a positive statistically significant association with delivery date, length of AZT use, maternal CD 4 % but not the maternal plasma RNA level.

CONCLUSION: Genotyping mutations associated with AZT resistance were seen in 200/0 of pregnant women with increasing prevalence during dl observation period and an association with length of drug exposure. ARV resistance to multiple agents was rare among pregnant women in this cohort; continued surveillance is going on as is the analysis of genotyping and subsequent clinical course among infected children.

Keywords: AEGIS, HIV Seropositivity, Nevirapine, Zidovudine, Anti-HIV Agents, HIV Infections, Acquired Immunodeficiency Syndrome, HIV, Mutation, HIV Protease, RNA-Directed DNA Polymerase, Treatment Refusal, Pregnant Women, Humans, Female, Child, Infant, Pregnancy, genetics

040711
B10049

Copyright © 2004 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.